ICR criticises NICE rejection of olaparib for advanced prostate cancer 06 Sep 2022 The Institute of Cancer Research, London, has expressed disappointment that NICE has confirmed its decision not to recommend olaparib for previously treated, hormone-relapsed metastatic prostate cancer. Find out more Show/Hide
Long-term benefit of radiotherapy confirmed in advanced prostate cancer 23 Aug 2022 Radiotherapy to the prostate alongside standard treatment can keep some men with advanced prostate cancer alive for longer without detriment to quality of life, long-term study results confirm. Find out more Show/Hide
ICR welcomes MHRA approval of 'search and destroy' prostate cancer treatment 11 Aug 2022 The Institute of Cancer Research, London, strongly welcomes the news that 177Lu-PSMA-617, a highly targeted radioactive drug, has been approved by the medicines regulator, the MHRA, for some patients with advanced prostate cancer. Find out more Show/Hide
'Man Van' launched to speed up early diagnosis of prostate cancer and improve healthcare access 21 Mar 2022